Understand the source comparison
ACE-031 vs Follistatin for Muscle Research UK 2026
All peptides and proteins discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical advice or clinical guidance. T
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- All peptides and proteins discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical advice or clinical guidance. This comparison examines two mechanistically distinct myostatin pathway research tools: ACE-031 (ActRIIA-Fc fusion decoy receptor) and Follistatin (FST-288 and FST-315 isoforms). Both inhibit myostatin (GDF-8) and related TGF-β superfamily members that suppress skeletal muscle growth, but through fundamentally different molecular mechanisms with distinct ligand selectivity profiles — making them complementary but non-interchangeable research tools for skeletal muscle biology, sarcopenia, muscular dystrophy, and cachexia research.